Agenus (AGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agenus (AGEN)

AGEN 3.960

+3.9%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Dodgy Ticker who wrote (74)	6/5/2006 10:18:58 AM
From: The Dodgy Ticker	Read Replies (1) of 146

Antigenics cancer vaccine misses study goal Mon Jun 5, 2006 10:06am ET CHICAGO, June 5 (Reuters) - Antigenics Inc. (AGEN.O: Quote, Profile, Research) on Monday said a late-stage human trial of its investigational vaccine for melanoma showed a "potential survival benefit" but did not reach its primary goal of proving the vaccine could beat a standard treatment. The study of 322 patients found that patients fared similarly on its drug, Oncophage, as on a standard treatment. Patients getting at least 10 doses of the drug showed a trend toward survival, the company said. The drug is being testing to treat metastatic melanoma, a form of skin cancer. Results were discussed at the annual meeting of the American Society of Clinical Oncology in Atlanta, Ga.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next